

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Abbott Molecular Assay, for melanocytic neoplasms, 883–884
- Abelson murine leukemia virus oncogene homolog 1, 828
- ABO blood group, 809–810
- AccuProbe assays, 788–789
- Acute leukemia with mixed lineage leukemia translocation, 825–826
- Acute lymphoblastic leukemia, 825–826
- Acute myeloid leukemia, 824–827, 831
- Acute promyelocytic leukemia, 824
- Adenoid cystic carcinoma, of breast, 902
- Adenoma-carcinoma sequence, in colorectal carcinoma, 836–838
- Affirm VPIII microbial identification test, 791–792
- Alloimmune thrombocytopenia, platelet antigens in, 814
- All-trans retinoic acid, for hematopoietic malignancies, 831
- AML 1 protein, in leukemia, 825
- Ampullary adenocarcinoma, 862
- Amsterdam criteria, for colorectal carcinoma, 839
- Anaplastic lymphoma kinase translocation assay, for lymphomas, 823–824
- Androgen receptors, in breast carcinoma, 896, 900–901
- Angiopoietins, in hepatic adenomas, 877
- AntagomiRs, 778
- Antibodies, in transfusion medicine, **805–816**
- Antigens, in transfusion medicine, **805–816**
- APC gene pathway
 - in colorectal cancer, 837–839, 852
 - in small intestinal adenocarcinoma, 863
- Apocrine carcinoma, of breast carcinoma, 896, 900
- Appendix, adenocarcinoma of, **861–866**
- ARID1 gene
 - in ovarian cancer, 912
 - in uterine carcinoma, 920
- Array comparative genomic hybridization, for melanocytic neoplasms, 885
- ATRA, for leukemia, 831

B

- B cells, clonal populations of, 818–820
- Basal-like subtype, of breast carcinoma, 895–896
- B-cell leukemia/lymphoma-2 (BCL-2) translocation assay, for lymphomas, 820–821
- BCL-2 gene, in breast carcinoma, 899
- BCL-2 like protein 11, 822
- BCL-2 translocation assay, for lymphomas, 820–821

- BCL-6 translocation assay, for lymphomas, 821
- BCR-ABL gene, in leukemia, 828
- Beta-catenin
- in cholangiocarcinoma, 877
 - in gall bladder adenoma, 878
 - in pancreatic neoplasms, 876
 - in uterine carcinoma, 917–918
- Biliary tract, neoplasms of, 878
- Biomarkers, microRNA, **773–786**
- BIOMED-2 protocol, for clonal T-cell populations, 820
- Blastomyces dermatitidis*, 788
- BLOODChip system, for transfusion medicine, 808
- BRAF gene
- in colorectal carcinoma, 845–846, 850, 852, 855
 - in melanocytic neoplasms, 883, 886–888
 - in ovarian cancer, 912
 - in small intestinal adenocarcinoma, 864
- Brain and acute leukemia, cytoplasmic, 828
- Branched DNA assays, 767–769, 790
- Breakpoint cluster region protein, in leukemia, 828
- Breast carcinoma, **891–909**
- basal-like subtype of, 895–896
 - classification of, 891–892
 - claudin low subtype of, 895–896
 - ductal carcinoma in situ type of, 902–903
 - ERBB2-enriched subtype of, 894–895
 - histologic subtypes of, 893, 895–902
 - adenoid cystic carcinoma, 902
 - apocrine carcinoma, 900
 - invasive lobular carcinoma, 897–898
 - invasive micropapillary carcinoma, 900
 - invasive papillary carcinoma, 899–900
 - medullary carcinoma, 901–902
 - metaplastic carcinoma, 901
 - mucinous carcinoma, 899
 - neuroendocrine carcinoma, 899
 - secretory carcinoma, 902
 - tubular carcinoma/cribiform carcinoma, 898–899
 - incidence of, 891
 - interferon-related group of, 896
 - luminal A subtype of, 892–893
 - luminal B subtype of, 894
 - molecular apocrine subtype of, 896
 - progression pathways for, 903
- Brenner tumors, 913
- Burkitt lymphoma, 820, 822

C

- Cadherins
- in breast carcinoma, 895–896

- in gastric carcinoma, 870
 - in hepatic adenomas, 877
 - in uterine carcinoma, 917–918
- Cancer, microRNA expression profiling for, **773–786**
- Candida*, 791–792
- Carcinoembryonic antigen, in breast carcinoma, 902
- Carcinosarcoma, uterine, 919–920
- CBFB gene, in leukemia, 825
- CCAAT enhancer binding protein alpha, in leukemia, 827
- CCND1 gene, in breast carcinoma, 899–900
- CDKN gene, in ovarian cancer, 913
- Celiac disease, small intestinal adenocarcinoma in, 862
- Cell-free nucleic acid amplification tests, 814
- Cellular myelocytomatosis translocation assay, for lymphomas, 821–822
- Chlamydia trachomatis*, 792–793
- Cholangiocarcinoma, 877–878
- Chromogenic in situ hybridization, 770
- Chromosomal aberrations, in hematopoietic malignancies, 831–832
- Chromosomal instability, in gastric carcinoma, 868
- Chronic myelogenous leukemia, 828, 831–832
- Chronic myelomonocytic leukemia, 831–832
- Clathrin chain polypeptide-like gene, in aplastic lymphoma, 823
- Claudin low subtype, of breast carcinoma, 895–896
- Clear cell carcinoma
 - ovarian, 912–913
 - uterine, 920–921
- C-MYC gene, in lymphomas, 821–822, 831
- Coccidioides immitis*, 788
- Colorectal carcinoma, 835–836
 - APC gene pathway in, 837, 839
 - classification of, 835–836, 843, 845–846
 - clinical features of, 836
 - epidemiology of, 836
 - hereditary nonpolyposis colon cancer (Lynch syndrome), 839–844
 - molecular genetics of, 836–837
 - pathology of, 846–848
 - pathophysiology of, 836–837
 - protective factors against, 837
 - risk factors for, 836
 - sporadic microsatellite instability, 846
 - testing for
 - algorithm for, 852–854
 - BRAF mutation, 855
 - germline, 852
 - KRAS mutation, 851, 855
 - lymph nodes, 854
 - mismatch repair, 847–848
 - MSI, 849–851
 - new methods for, 854
 - pitfalls in, 848–849
 - predictive markers for, 854–855

Colorectal (*continued*)

- quality assurance in, 848
 - reporting results of, 851
 - staging, 854
 - treatment of, 855–856
 - Vogelstein model of, 837, 839
- Colton blood group system, 811
- Comparative genomic hybridization, for breast carcinoma, 894
- Conventional cytogenetics (CCs), for lymphomas and leukemias, 822–825
- Core-binding factor, in leukemia, 825
- CpG island methylator (CIMP) phenotype, of colorectal carcinoma, 843–846, 851, 854
- Cribriform carcinoma, of breast, 898–900
- Cromer blood group system, 812
- CTLA-4 antibody, for melanocytic neoplasms, 886
- CTNNB1 gene
 - in ovarian cancer, 913
 - in uterine carcinoma, 917–918
- Cyclin D1, in pancreatic neoplasms, 876
- Cyclin-D 1 (BCL-2) gene translocation assay, for lymphomas, 821
- Cytogenetics, for lymphomas and leukemias, 822–825
- Cytokeratins, in breast carcinoma, 895, 902

D

- Dabrafenib, for melanocytic neoplasms, 887
- Dacarbazine, for melanocytic neoplasms, 886
- DEK-NUP214 chimeric protein, in leukemia, 826
- Denaturing gradient gel electrophoresis, 762–763
- Diego blood group system, 811
- Digital PCR, 795
- DNA assays, branched, 767–769
- DNA sequencing, 757–760
- Dombrock blood group system, 811
- Ductal adenocarcinoma, of pancreas, 876
- Ductal carcinoma in situ, 902–903
- Duffy blood group system, 811

E

- Economic issues, in molecular pathology, 751
- Ecotropic viral integration site-1 gene, 826
- EMA gene, in breast carcinoma, 900, 902
- Endometrioid carcinoma, ovarian
 - high-grade, 914
 - low-grade, 913
- Endothelins, epigenetic inactivation of, in colorectal cancer, 856
- Enterococcus*, 791
- Enterococcus faecalis*, 791
- Epidermal growth factor
 - in breast carcinoma, 895, 902
 - in uterine carcinoma, 920

Epigenetic inactivation, of endothelins, in colorectal carcinoma, 856
Epithelial cell adhesion molecule, in colorectal carcinoma, 841
Epithelial membrane antigen, in breast carcinoma, 900
Epithelial-mesenchymal transition, in breast carcinoma, 903
ERBB2 gene, in breast carcinoma, 896, 898
ERBB2-enriched subtype, of breast carcinoma, 894–895
Escherichia coli, 791
Esophageal neoplasms, **867–873**
ESR-1, gene, in breast carcinoma, 899
Estrogen receptor(s), in breast carcinoma, 903
Estrogen receptor gene (ESR-1), in breast carcinoma, 892, 894, 899
ETSV6-NTRK3 gene fusion, in breast carcinoma, 902
EV11 gene, in leukemia, 826
Evaluation of Genomic Applications in Practice and Prevention, testing recommendations of, 853

F

Fine needle aspiration samples, microRNA technology using, 780–781
FLT3 gene, in leukemia, 827
Fluorescent in situ hybridization (FISH), 770
 for gastric carcinoma, 869
 for leukemias, 824–829
 for lymphomas, 821–823
 for melanocytic neoplasms, 883–885
Fluorescent resonance energy transfer (FRET)
 for microbiology, 794
 for platelet antigen genotyping, 812
Fms-related tyrosine kinase 3 gene, in leukemia, 827
Follicular lymphoma, 820–821
Formalin-fixed tissues, microRNA technology using, 779–781

G

Gall bladder, neoplasms of, 878
Gardnerella vaginalis, 791–792
Gastric neoplasms, **867–873**
GCDPF, in breast carcinoma, 900
Gel electrophoresis, denaturing gradient, 762–763
Gemcitabine, for pancreatic neoplasms, 876
Genotyping, of red cells, 809–812
Gen-Probe tests, for microbiology, 788–789
Germline mutations
 in colorectal carcinoma, 848, 852
 in immunoglobulins, 818
 in small intestinal adenocarcinoma, 864
GUCY2C test, in colorectal carcinoma, 854
Gynecologic cancers, **911–925**
 ovarian, 911–915
 uterine, 915–921

H

- Hairy cell leukemia, 823–824
- HEA BeadChip system, for transfusion medicine, 808
- Helicobacter pylori* infections, gastric carcinoma in, 868
- Hematopoietic neoplasms, molecular tests for, **817–833**
 - clonal T- and B-cell populations, 818–820
 - leukemias, 824–829
 - lymphomas, 820–824
 - myelodysplastic syndromes, 829–831
 - myeloproliferative neoplasms, 829–830
- Hepatitis C virus, 796
- Hepatocellular carcinoma, 877
- Hepatomegaly nuclear factor 1, in hepatic adenomas, 877
- HER-2 gene
 - in breast carcinoma, 894–895
 - in gastric carcinoma, 869–870
 - in uterine carcinoma, 919–920
- Hereditary nonpolyposis colon cancer (Lynch syndrome), 839–844, 852
 - uterine cancer and, 916
- Herpes simplex virus, 794–795
- High-resolution melting analysis, 763
- Histoplasma capsulatum*, 788
- Hologic-Gen-Probe microbiology tests, 794
- Human immunodeficiency virus, 794–796
- Human leukocyte antigens, in platelets, 812–814
- Human papillomavirus, hybrid capture for, 766–767
- Human platelet antigens nomenclature system, 812–813
- Hybrid capture technique, 766–767, 789–790
- Hybridization-protection assays, for microbiology, 788–789

I

- Imatinib, for melanocytic neoplasms, 887–888
- Immunoglobulin(s), clonal populations of, 818–820
- Immunohistochemistry
 - for breast carcinoma, 894–895
 - for colorectal carcinoma, 849
 - for gastric carcinoma, 869
 - for small intestinal adenocarcinoma, 863
- Influenza virus, 796
- In situ hybridization, 770, 790–791. *See also* Fluorescent in situ hybridization (FISH).
- Interferon(s)
 - in breast carcinoma, 896
 - in melanocytic neoplasms, 886
- Interleukin(s), for melanocytic neoplasms, 886
- International Society of Blood Transfusion, notation system of, 809
- Invasive lobular carcinoma, 897–898
- Invasive micropapillary carcinoma, of breast, 900
- Invasive papillary carcinoma, of breast, 899–900
- Ipilimumab, for melanocytic neoplasms, 886–888

IRF genes, in breast carcinoma, 901
Isocitrate dehydrogenase, in leukemias, 828

J

JAK2 gene, in myeloproliferative syndrome, 829–830
Juvenile (secretory) carcinoma, of breast, 902

K

Kell blood group system, 811
Kidd blood group system, 811
Kirschen rat sarcoma viral oncogene. *See* KRAS gene.
KIT gene
 in breast carcinoma, 902
 in leukemia, 827
 in melanocytic neoplasms, 883, 886–888
 inhibitors of, 887–888
Klebsiella pneumoniae, 791
Knops blood group system, 812
KRAS gene
 in colorectal carcinoma, 845–846, 851, 855
 in ovarian cancer, 912–913
 in pancreatic neoplasms, 876
 in small intestinal adenocarcinoma, 863–864

L

Late breaker techniques, for microbiology, 799
Leukemias, molecular tests for, 821, 824–829
LifeCodes RBC system, for transfusion medicine, 808
Liver, neoplasms of, 876–878
Luminal A type, of breast carcinoma, 892
Luminal B type, of breast carcinoma, 894
LW blood group system, 811–812
Lymph nodes, investigation of, in colorectal carcinoma, 854
Lynch syndrome, 839–844, 852, 916–917

M

Major breakpoint region
 in BCL-2 gene, 820
 in BCL-6 gene, 821
Malignant melanoma. *See* Melanocytic neoplasms.
Malignant mixed müllerian tumor, uterine, 919–920
MALT lymphomas, 822–823
Mantle cell lymphoma, 821
Mass spectroscopy, for microbiology, 798–799
Matrix-assisted laser desorption/ionization time of flight (MALDI-TOF), for microbiology,
 798–799
Medullary carcinoma, of breast, 901–902
Megakaryoblastic leukemia, 826

- Melanocytic neoplasms, **881–890**
 - differential diagnosis of, 882
 - genetics of, 883
 - testing of, 883–886
 - treatment of, 886–888
 - types of, 882
- Melanoma. See Melanocytic neoplasms.
- MEN1 gene, in pancreatic neoplasms, 876
- Metaplastic carcinoma, of breast, 901
- Microbiology, diagnostic, **787–803**
 - highly multiplexed PCR panels for, 796–797
 - late breaker techniques for, 799
 - mass spectroscopy in, 798–799
 - next-generation sequencing for, 797–798
 - nucleic acid amplification tests for, 792–796
 - probe techniques for, 788–792
- Micropapillary carcinoma, invasive, 900
- MicroRNA expression profiling, **773–786**
 - applications of, 776–777
 - clinical perspective of, 775–776
 - diagnostic implications of, 782
 - for colorectal cancer, 855–856
 - in clinical specimens, 777–778
 - in formalin-fixed tissues, 779–781
 - isolation step in, 781
 - overview of, 773–774
 - prognostic implications of, 782
 - purification in, 778–779
- Microsatellite instability
 - in colorectal carcinoma, 843–845, 847–851
 - in gastric carcinoma, 869
 - in small intestinal adenocarcinoma, 863–864
 - in uterine carcinoma, 916
- Mismatch repair gene (MMR) defects
 - in colorectal carcinoma, 839, 841–842, 847–849, 853
 - in small intestinal adenocarcinoma, 863–864
- Mixed lineage leukemia, 825–826
- MKL1 gene, in leukemia, 826
- MLH genes
 - in colorectal carcinoma, 839–840, 848, 850–852
 - in small intestinal adenocarcinoma, 864
 - in uterine carcinomas, 916
- MLL gene, in leukemias, 825–826, 828
- MMR (mismatch repair gene) defects
 - in colorectal carcinoma, 839, 841–842, 847–849, 853
 - in small intestinal adenocarcinoma, 863–864
- MNS blood group system, 810–811
- Molecular apocrine subtype, of breast carcinoma, 896
- Molecular beacon technology, for microbiology, 794
- Molecular pathology and diagnosis
 - impact of, **749–751**

- in biliary tract neoplasms, 878
 - in breast carcinoma, **891–909**
 - in colorectal carcinomas, **835–859**
 - in cutaneous melanocytic neoplasms, **881–890**
 - in esophageal neoplasms, **867–873**
 - in gallbladder neoplasms, 878
 - in gastric neoplasms, **867–873**
 - in gynecologic cancers, **911–925**
 - in hematopoietic neoplasms, **817–833**
 - in liver neoplasms, 876–878
 - in pancreatic neoplasms, 875–876
 - in small intestinal and appendiceal neoplasms, **861–866**
 - in transfusion medicine, **805–816**
 - microbiology, **787–803**
 - microRNAs in, **773–786**
 - techniques for, **753–772**
- Molecular tree technique, for microbiology, 790
- MSH genes
 - in colorectal carcinoma, 839, 841, 848–849, 851–852
 - in uterine carcinoma, 916, 920
- MSI. *See* Microsatellite instability.
- Mucinous carcinoma, of breast, 899
- Mucosal-associated lymphoid tissue translocation assay, for lymphomas, 822–823
- MultiCode RTx system, for microbiology, 794–795
- Multiplex polymerase chain reaction, 755
 - for colorectal carcinoma, 854–855
 - for transfusion medicine, 808
- MYC gene, in breast carcinoma, 900
- Mycobacterium*, nontuberculous, 788
- Mycobacterium tuberculosis*, 788–789
- Myelodysplastic syndromes, 829–831
- Myeloproliferative neoplasms, 829–830
- MYH11 gene, in leukemia, 825
- Myoepithelial cells, in breast carcinoma, 903

N

- NAATs (nucleic acid amplification tests), 792–796, 814
- National Comprehensive Cancer Network guidelines, for colorectal carcinoma, 849, 852–853
- Neisseria gonorrhoea*, 788, 792–793
- NeoGenomics probes, for melanocytic neoplasms, 883–884
- Neuroendocrine carcinoma, of breast, 899
- Nevi. *See* Melanocytic neoplasms.
- Next-generation sequencing, for microbiology, 797–798
- Northern hybridization, 763–764
- NPM1 gene, in leukemia, 826–827
- Nucleic acid amplification tests
 - cell-free, for transfusion medicine, 814
 - for microbiology, 792–796
- Nucleophosmin gene, in aplastic lymphoma, 823

O

- Octreotide, for pancreatic neoplasms, 876
- Oncotype D_x colon cancer assay, 854–855
- One-step nucleic acid amplification, for colorectal carcinoma, 854
- Ovarian cancer, 911–915
 - carcinogenesis in, dualistic model of, 914–915
 - incidence of, 911
 - type I
 - clear cell carcinoma, 912–913
 - low-grade endometrioid carcinoma, 913
 - low-grade serous carcinoma, 912
 - mucinous carcinoma, 913
 - type II
 - high-grade endometrioid carcinoma, 914
 - serous carcinoma, 913–914

P

- p53 gene
 - in breast carcinoma, 894–895, 899
 - in gall bladder adenocarcinoma, 878
 - in gall bladder adenoma, 878
 - in ovarian cancer, 914
 - in pancreatic neoplasms, 876
 - in small intestinal adenocarcinoma, 863
 - in uterine carcinoma, 919–920
- Pancreas, neoplasms of, 875–876
- Paracoccidioides brasiliensis*, 788
- PAX8 gene, in ovarian cancer, 914
- PBX1 gene, in leukemia, 828
- PCR. See Polymerase chain reaction.
- Peptide nucleic acid fluorescence in situ hybridization, for microbiology, 790–791
- Personalized medicine, microRNA expression profiling for, **773–786**
- Phenotyping, of red cells, 809–812
- Philadelphia chromosome, 828–829
- PIK3CA gene
 - in breast carcinoma, 894, 900
 - in ovarian cancer, 912–914
 - in uterine carcinoma, 917, 920
- Plasma, microRNA purification in, 778–779
- Plasma cell myelomas, 822
- Platelet antigens and antibodies, in transfusion medicine, **805–816**
- PLEKHA7 gene, in breast carcinoma, 898
- PMS2 gene
 - in colorectal carcinoma, 839–840, 848–849
 - in small intestinal adenocarcinoma, 864
 - in uterine carcinomas, 916
- Polymerase chain reaction, 753–754
 - for colorectal carcinoma, 849–850, 854–855
 - for immunoglobulin rearrangement, 819

- for leukemias, 826–829
- for lymphomas, 820–824
- for microbiology, 795–797
- for platelet antigen genotyping, 812
- for T-cell receptor rearrangement, 819–820
- for transfusion medicine, 808–814
- highly multiplexed, 796–797
- in microRNA purification, 779, 781
- multiplex, 755
- real-time, 754–755, 781
- reverse transcriptase, 754

Pre-B-cell leukemia transcription factor 1, 828

Probe techniques, for microbiology, 788–792

Progesterone receptors, in breast carcinoma, 903

Promyelocytic leukemia gene, 824

Pseudomonas aeruginosa, 791

PTEN gene

- in breast carcinoma, 901
- in ovarian cancer, 913–914
- in uterine carcinoma, 916–917

Pyrosequencing, 759, 761–762

Q

Quality assurance, in testing

- for colorectal cancer, 750–751
- for small intestinal adenocarcinoma, 864–865

QUASAR study, for colon cancer, 854–855

R

RAS genes, in melanocytic neoplasms, 883

RAS-RAF-MEK-ERK pathway, in uterine carcinoma, 917

RASSF1A gene, in uterine carcinoma, 917

RBM15 gene, in leukemia, 826

Real-time polymerase chain reaction, 754–755, 781

Red blood cells antigens and antibodies, in transfusion medicine, **805–816**

Respiratory syncytial virus, 796

Respiratory viruses, panels for, 796–797

Restriction fragment length polymorphism analysis, 764, 808

Retinoic acid receptor-alpha (RARA) gene, 824

Reverse line-blot hybridization, 764–766

Reverse transcriptase, in microRNA purification, 779

Reverse transcriptase polymerase chain reaction, 754

Rh blood group, 810

Ribophorin 1 gene, in leukemia, 826

RNA-binding motif protein 15, in leukemia, 826

RPN1 gene, in leukemia, 826

RUN1 gene, in leukemia, 828

Run-related transcription factor 1 gene, in leukemia, 824–825

S

- Sanger sequencing, for transfusion medicine, 808
- Secretory carcinoma, of breast, 902
- Serous carcinoma
 - ovarian
 - high-grade, 912–914
 - low-grade, 912
 - uterine, 919
- Serrated polyp pathway, in colorectal carcinoma, 840, 845–846
- Sexually transmitted diseases, NAATs for, 792–794
- Silver in situ hybridization, for gastric carcinoma, 869–870
- Single nucleotide polymorphisms
 - in platelets, 813
 - in red cells, 809–812
- Smad4 gene
 - in pancreatic neoplasms, 876
 - in small intestinal adenocarcinoma, 863
- Small intestine, adenocarcinoma of, **861–866**
- Southern blot hybridization, 763–764
 - for immunoglobulin rearrangement, 819
 - for lymphomas, 822
 - for T-cell receptor rearrangement, 819
- Spindle cells, in breast carcinoma, 901
- Spitzoid lesions. *See* Melanocytic neoplasms.
- Squamous cells, in breast carcinoma, 901
- Staphylococcus*, 791
- STAT1 gene, in breast carcinoma, 901
- Stool DNA, in colorectal carcinoma, 854
- Strand displacement amplification, 755–756, 792

T

- T cells, clonal populations of, 818–820
- TaqMan test, for microbiology, 794
- T-cell factor 3, in leukemia, 828
- TCF3 gene, in leukemia, 828
- Teratomas, ovarian, 913
- TMSB10 gene, in breast carcinoma, 898
- TOP2A gene, in breast carcinoma, 901
- Transcription-mediated amplification, 756–757, 792–793
- Transfusion medicine, molecular testing in, **805–816**
 - advantages of, 806–807
 - cell-free nucleic acid, 814
 - limitations of, 807
 - notation for, 809
 - platelet antigen expression in, 812–814
 - red cell antigen expression in, 809–812
 - techniques for, 807–808
 - terminology of, 809
- Trastuzumab

for gastric carcinoma, 869–870

for uterine carcinoma, 920

Trichomonas vaginalis, 791–792

TRK fused gene, in aplastic lymphoma, 823

Tropomyosins, in aplastic lymphoma, 823

Tubular carcinoma, of breast, 898–900

Tumor necrosis factor, in breast carcinoma, 901

U

Uterine carcinomas, 915–921

treatment of, 918

type I, 915–918

type II, 918–921

V

Vascular endothelial growth factor

in gastric carcinoma, 869

in small intestinal adenocarcinoma, 863

Vemurafenib, for melanocytic neoplasms, 886–887

Vogelstein model, for colorectal carcinoma, 837–839

VP111 microbial identification test, 791–792

W

Wilms' tumor gene, in leukemia, 827

Wnt/b-catenin pathway

in breast carcinoma, 899

in ovarian cancer, 913

WT1 gene, in leukemia, 827

X

xTAG technology, 755

Z

Zelboraf, for melanocytic neoplasms, 886–887